China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb…

Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion.

Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan.

The collaboration covers four oncology and haematology programmes originating from Hengrui, four immunology assets from BMS, and another five novel programmes to be jointly developed using Hengrui’s discovery platforms. All 13 programmes are at the preclinical stage, according to a filing with the Hong Kong stock exchange.

BMS has agreed to pay Hengrui up to US$950 million in near-term consideration, including an upfront payment of US$600 million. The overall deal value could reach about US$15.2 billion if all development, regulatory and commercial milestones are met and options on the co-discovery projects are exercised.

BMS will pay Hengrui up to US$950 million in near-term consideration, including an upfront payment of US$600 million. Photo: Handout

Hengrui will also be entitled to tiered royalties on sales of partnered products outside mainland China, Hong Kong and Macau.

Don't Miss:

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Make home ownership a 5-year plan goal, Legco president says

Hong Kong a ‘trusted partner’ to drive Central Asia growth, city leader says

More Chinese pet owners choose TCM for chronic pet illnesses using herbs, bee stings, acupuncture

Iranians recount horrors of suspected US missile attack on first day of war

2 Hong Kong travel agencies, guide stripped of licences over ‘coerced shopping’